Samuel Liwei Leong, Lawton Murdolo, Janesha C Maddumage, Marios Koutsakos, Katherine Kedzierska, Anthony W Purcell, Stephanie Gras, Emma J Grant
{"title":"新型流感衍生 HLA-B*18:01 限制性表位的特征描述","authors":"Samuel Liwei Leong, Lawton Murdolo, Janesha C Maddumage, Marios Koutsakos, Katherine Kedzierska, Anthony W Purcell, Stephanie Gras, Emma J Grant","doi":"10.1002/cti2.1509","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8<sup>+</sup> T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8<sup>+</sup> T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8<sup>+</sup> T cell responses across broad populations. Consequently, the rational design of a CD8<sup>+</sup> T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Using CD8<sup>+</sup> T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01<sup>+</sup> individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8<sup>+</sup> T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP<sub>219</sub> peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"13 5","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1509","citationCount":"0","resultStr":"{\"title\":\"Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes\",\"authors\":\"Samuel Liwei Leong, Lawton Murdolo, Janesha C Maddumage, Marios Koutsakos, Katherine Kedzierska, Anthony W Purcell, Stephanie Gras, Emma J Grant\",\"doi\":\"10.1002/cti2.1509\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Objectives</h3>\\n \\n <p>Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8<sup>+</sup> T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8<sup>+</sup> T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8<sup>+</sup> T cell responses across broad populations. Consequently, the rational design of a CD8<sup>+</sup> T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Using CD8<sup>+</sup> T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01<sup>+</sup> individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8<sup>+</sup> T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP<sub>219</sub> peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.</p>\\n </section>\\n </div>\",\"PeriodicalId\":152,\"journal\":{\"name\":\"Clinical & Translational Immunology\",\"volume\":\"13 5\",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-05-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1509\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1509\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1509","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
尽管有疫苗可用,但季节性流感病毒每年仍会导致大约 65 万人死亡。CD8+ T 细胞通常能识别来自内部结构和非结构性流感蛋白的流感衍生肽,是未来疫苗设计的一个有吸引力的途径,因为它们能降低感染不同流感病毒株后的疾病严重程度。CD8+ T 细胞能识别由高度多态的人类白细胞抗原 I 类分子(HLA-I)呈现的肽。每种 HLA-I 变体都有不同的肽结合偏好,这对设计能在广泛人群中引起 CD8+ T 细胞反应的疫苗构成了重大障碍。因此,要合理设计 CD8+ T 细胞介导的疫苗,就必须鉴定出限制于一系列不同 HLA 分子的高免疫原性肽。 方法 在此,我们评估了最近发表的六种新型流感衍生肽的免疫原性,这些肽是通过质谱分析鉴定的,并预测能与流行的 HLA-B*18:01 分子结合。 结果 我们使用 CD8+ T 细胞活化试验和蛋白质生物化学方法表明,3/6 种新型多肽在几个 HLA-B*18:01+ 的个体中具有免疫原性,并证实了它们的 HLA-B*18:01 限制。随后,我们比较了 CD8+ T 细胞对之前发现的高免疫原性 HLA-B*18:01 限制性 NP219 肽的反应。通过 X 射线晶体学,我们首次解析了 HLA-B*18:01 呈现免疫原性流感衍生肽的晶体结构。最后,我们剖析了首个针对 HLA-B*18:01 限制性病原体衍生肽的特异性 TCR 反应谱,确定了针对四种肽中每一种肽的私有和限制性反应谱。 结论 总的来说,这些新型免疫原性多肽的特征描述提供了更多的 HLA-B*18:01 限制性疫苗靶标,这些靶标来自基质蛋白 1,也可能来自流感病毒的非结构蛋白和 RNA 聚合酶催化亚基。
Characterisation of novel influenza-derived HLA-B*18:01-restricted epitopes
Objectives
Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.
Methods
Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.
Results
Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01+ individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP219 peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.
Conclusion
Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.
期刊介绍:
Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.